Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. - Wikidata - wikimedia - TriplyDB

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

http://www.wikidata.org/entity/Q37806773

about

Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update Genetic interstitial lung disease Recent progress in pancreatic cancer Genome sequencing identifies a basis for everolimus sensitivity Rapamycin and rapalogs for tuberous sclerosis complex Cytotoxic and targeted therapy for hereditary cancers Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis The neurology of mTOR Ten things you should know about protein kinases: IUPHAR Review 14 Optimizing treatments for lymphangioleiomyomatosis Harnessing the power of metabolism for seizure prevention: focus on dietary treatments Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift The molecular biology of WHO grade I astrocytomas Potential for treatment of severe autism in tuberous sclerosis complex Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target Pathological and molecular advances in pediatric low-grade astrocytoma Real-time monitoring of tumorigenesis, dissemination, & drug response in a preclinical model of lymphangioleiomyomatosis/tuberous sclerosis complex Melatonin improves sleep in children with epilepsy: a randomized, double-blind, crossover study.Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex.Convulsive seizures from experimental focal cortical dysplasia occur independently of cell misplacement.Stochastic model of Tsc1 lesions in mouse brain Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury Therapeutic targeting of cancers with loss of PTEN function.Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients?Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy Diagnostic methods and treatment options for focal cortical dysplasia DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics.Epidemiologic and molecular prognostic review of glioblastoma Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC)Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57BL/6 mice Assessing the clinical utility of cancer genomic and proteomic data across tumor types.The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex.Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex.

P2860

Q22305852-037C21F6-1C09-4987-8C7B-5ADD1AF3E318 Q24597688-32EADB53-C263-499C-8FBD-FBF6C0E53797 Q24626239-35E7E454-A031-4C33-AD71-46D462872619 Q24626346-BEE6479D-1964-4DF6-959D-2B6AAAB312A1 Q24631915-9AA9D64F-0EFC-49A8-817B-5EE67F14ACFF Q26471128-626EB693-3E66-49EA-9830-4898178DB146 Q26739366-3961C499-5E8A-4E73-976F-0B9A20AEDFED Q26799757-59E27FC7-5559-4724-8067-F93F0BB6ABB3 Q26824286-DCAB27AC-CDF8-4845-B97F-7CE7CD5E3D3E Q26849417-B53145E0-5C7A-470D-B1BD-FDF9DBE781FE Q26865250-A4FBE375-4082-4633-B46D-8A5807E6647B Q26991869-38D119AD-9D65-41C7-81E3-D3B4CC19250E Q26999365-876B179C-3820-470E-8893-8E79240D41B0 Q27010414-F0F65C81-5DAF-41C3-B2C6-AED382EB1A6B Q27021739-97230132-0CC5-4D85-B9B1-F6A4F029CAEC Q27024547-3B328AB8-6A8D-4A99-A3B4-6E3D2F66F909 Q27026123-2B8E60BB-4623-450F-9F94-10667DFCA767 Q27301399-F0D5B654-F9C4-4D2C-98CC-6EA6ED6969BA Q27303807-DCA70536-88FD-42F5-A762-E5B5111342E4 Q27308042-BCDB9B24-C9F7-4781-9E40-83E74BDDB737 Q27314858-27B71FCA-1E4F-4A90-9F79-81CAF818AEC9 Q27319406-84BAD399-E9BB-4876-A171-81F68E1DA329 Q27319659-ED25ED5E-B64C-4B9E-A3A8-1FA101458CA7 Q27852764-EAA9BB0B-BA0A-4EDE-9A95-0D8BEB225063 Q28067037-65A78EED-BEC6-4BA7-9EC1-3EE68DD3187B Q28071388-BF9E1113-A1A0-45B8-BB63-C952868AEB58 Q28075954-59136468-3686-4B1B-9CC3-FDCD6FA69F60 Q28078328-C4FCCF26-B2D8-4EA9-A7D6-6303E1716B05 Q28081144-9F9F6211-833F-4AAF-8F28-E6531131989D Q28303693-9EB35734-0C46-434A-AD64-35DA7EA75FD5 Q28394524-3D6C089A-3DBE-492D-B596-A458FCE4A977 Q28395302-F9E95E32-C60B-4DC8-A6C0-12C0B1EAB3F1 Q28476810-337E6D7F-290A-4C4E-81A1-6B12EED8B31E Q28481010-7F467CD4-7075-4F43-9164-A0D902FDDB91 Q28486250-A06B3B49-8FCA-4B76-8181-2C24CA556360 Q30422022-CC6CFB10-974B-47F6-A189-F2C41E59E531 Q30444988-D0CA7D64-3111-45C4-9232-4159BAFE705E Q30487077-7A0C0DD6-03EE-4074-832B-96C81C2E08F3 Q30518266-B863E649-1008-4183-B825-6DF7A3F6DCA0 Q30531079-3E16C7A4-F1FE-4D9E-9F9E-FA06134F2427

P2860

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

http://www.wikidata.org/entity/Q37806773

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

@en

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

@nl

type

label

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

@en

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

@nl

prefLabel

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

@en

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

@nl

P1433

Q37806773-55E45527-4F26-49F6-81E9-A04569E2A477

P1476

Q37806773-9866FB55-1630-4717-9D58-4F3D8E570674

P2093

Q37806773-2E25127E-AF48-4E2E-98E3-EAD107B6B4DE

Q37806773-337097B0-634A-4F1A-B045-E0E25323CDC4

Q37806773-3E58E2F3-8EC8-448F-AF68-87660DB8BBD4

Q37806773-6808D116-1658-41E0-BD79-CF0301C5FD76

Q37806773-70D0A72D-E5FE-4D24-A98C-6B1FA3ABD9D3

Q37806773-9A1D7ACB-8A7D-400A-8EDF-D41869DE0358

Q37806773-B367F4A6-89F4-40AF-BBF9-ED24171F67BF

Q37806773-BDE23CAF-3089-44B6-A8A3-003D851E463D

Q37806773-D5878768-9B9E-4E4C-BD0D-7DDE72D863C6

Q37806773-F55C4A03-0A37-4C13-BB15-ED260649AD52

P304

Q37806773-390655A3-47CC-4A9C-8A25-F87F8C229080

P31

Q37806773-3560A4AB-D70E-45FB-9C65-2E085B5185FA

P356

Q37806773-79F8E1B0-89E4-450E-BEEE-47B9667AC112

P407

Q37806773-5F885C60-E706-4AAA-9083-8F8058CB99D2

P433

Q37806773-76B6A196-A202-4FB8-9A82-2B4A99F18341

P478

Q37806773-F6E63C33-D6E6-4096-BFFD-62BC1E22DFD4

P577

Q37806773-93DFAF7A-CDC8-4138-93EC-D76B4B4C2C31

P5875

Q37806773-443763A3-10C0-41DF-88DE-565ACF95FC5A

P698

Q37806773-E63E6ECA-B246-4D8E-A682-21EAC60B0463

P356

P1433

The New England Journal of Medicine

P1476

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.

@en

P2093

Anna Byars

http://www.w3.org/2001/XMLSchema#string

Cynthia Tudor

http://www.w3.org/2001/XMLSchema#string

Darcy A Krueger

http://www.w3.org/2001/XMLSchema#string

David Neal Franz

http://www.w3.org/2001/XMLSchema#string

Karen Agricola

http://www.w3.org/2001/XMLSchema#string

Katherine Holland

http://www.w3.org/2001/XMLSchema#string

Kimberly A Wilson

http://www.w3.org/2001/XMLSchema#string

Marguerite M Care

http://www.w3.org/2001/XMLSchema#string

Prajakta Mangeshkar

http://www.w3.org/2001/XMLSchema#string

Tarek Sahmoud

http://www.w3.org/2001/XMLSchema#string

P304

1801-1811

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1001671

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

363

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47675139

http://www.w3.org/2001/XMLSchema#string

P698

21047224

http://www.w3.org/2001/XMLSchema#string